Share this article
Share this article
- With the indication expanded to pediatric patients, ALK Canada now provides adults and children a SLIT-tablet option to treat allergies to ragweed pollen, one of the most common allergens found in the provinces of Ontario and Quebec -
MISSISSAUGA, ON, Dec. 22, 2020 /CNW/ Today ALK, a global, research-driven pharmaceutical company, announced that Health Canada has approved once-daily RAGWITEK® (Standardized Allergen Extract, Short Ragweed (Ambrosia artemisiifolia) Sublingual Tablet) for the treatment of moderate to severe ragweed pollen allergies in children age five and older. RAGWITEK had received Health Canada approval for adult use in 2014.